secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193125-23-202313
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q2 net product revenues up 43% to $306M; Vaishnaw steps down as President
--------------------------------------------------------------------------------

- Net product rev $306M (+43% YoY); GAAP net loss $276M ($2.21/share), non-GAAP net loss $202M ($1.62/share).
- AMVUTTRA rev $132M, ONPATTRO $91M, GIVLAARI $58M, OXLUMO $24M; total TTR growth 72% in U.S.
- Reiterated 2023 guidance: combined net product rev $1.2B-$1.285B.
- U.S. Attorney's Office closed ONPATTRO marketing investigation with no action.
- President Akshay Vaishnaw transitions to part-time Chief Innovation Officer, effective Oct 2, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/0001193125-23-202313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/d472276d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-202313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer